Lead Product(s) : RP-001
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : TVM Capital Life Science
Deal Size : $24.0 million
Deal Type : Financing
Details : Recurv Pharma will use the funding in the development of a novel taxane therapy, RP-001, therapy to treat solid tumors. RP-001 is a new chemical entity (NCE) delivered in a nano-emulsion formulation that focuses the drug delivery to the tumor, sparing he...
Brand Name : RP-001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 03, 2023
Lead Product(s) : RP-001
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : TVM Capital Life Science
Deal Size : $24.0 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?
Reset All
